Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | MTTP | P55157 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11086275 | 0.85 | APEX1 (0.41) | APEX1KMT2ATHRBTDP1PDK2 | |
| SCHEMBL5863723 | 0.85 | THRB (0.46) | APEX1THRBTDP1PDK2MTTP | |
| Hydrochloric Acid SCHEMBL6777668 | 0.84 | THRB (0.44) | APEX1THRBTDP1PDK2MTTP | |
| SCHEMBL6777657 | 0.84 | APEX1 (0.40) | APEX1THRBTDP1MTTP | |
| SCHEMBL10778218 | 0.83 | APEX1 (0.42) | APEX1KMT2ATHRBTDP1PDK2 | |
| Propionamide SCHEMBL27574379 | 0.83 | THRB (0.38) | APEX1KMT2ATHRBTDP1MTTP | |
| SCHEMBL10995584 | 0.81 | APEX1 (0.40) | APEX1KMT2ATHRBTDP1MTTP | |
| SCHEMBL7045213 | 0.80 | MTTP (0.39) | APEX1PDK2MTTP | |
| SCHEMBL11084778 | 0.79 | SCN1A (0.41) | KMT2A | |
| SCHEMBL6769789 | 0.79 | AKR1C1 (0.35) | APEX1KMT2ATHRBTDP1MTTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030120-B2 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | OHKURA NAOTO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6777414-B1 | INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| EP-1180514-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | APOB, NCEH1, LIPC | APEX1 3633/4885KMT2A 2580/4885THRB 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.